Linear clinical progression, independent of age of onset, in Niemann–Pick disease, type C

Niemann–Pick disease, type C is a neurodegenerative, lysosomal storage disorder with a broad clinical spectrum and a variable age of onset. The absence of a universally accepted clinical outcome measure is an impediment to the design of a therapeutic trial for NPC. Thus, we developed a clinical severity scale to characterize and quantify disease progression. Clinical signs and symptoms in nine major (ambulation, cognition, eye movement, fine motor, hearing, memory, seizures, speech, and swallowing) and eight minor (auditory brainstem response, behavior, gelastic cataplexy, hyperreflexia, incontinence, narcolepsy, psychiatric, and respiratory problems) domains were scored. Data were collected from 18 current NPC patients and were extracted from records of 19 patients. Both patient cohorts showed a linear increase in severity scores over time. Cross‐sectional evaluation of current patients showed a linear increase in the severity score. Longitudinal chart review of historical data demonstrated that although age of onset varied significantly, the rate of progression appeared linear, independent of age of onset, and similar in all patients. Combining the data from both cohorts, disease progression could be modeled by the following equation: Ŝt0+x = Ŝt0 + 1.87x; where Ŝt0 is the initial score and Ŝt0+x is the predicted future score after x years. Our observation that disease progression is similar across patients and independent of age of onset is consistent with a biphasic pathological model for NPC. This scale may prove useful in the characterization of potential biomarkers, and as an outcome measure to monitor disease progression in NPC patients. © 2009 Wiley‐Liss, Inc.

[1]  H. Runz,et al.  NPC‐db, a Niemann‐Pick type C disease gene variation database , 2008, Human mutation.

[2]  J. Repa,et al.  Liver X Receptor Activation Enhances Cholesterol Loss from the Brain, Decreases Neuroinflammation, and Increases Survival of the NPC1 Mouse , 2007, The Journal of Neuroscience.

[3]  M. Patterson,et al.  Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study , 2007, The Lancet Neurology.

[4]  G. Besley,et al.  The natural history of Niemann–Pick disease type C in the UK , 2007, Journal of Inherited Metabolic Disease.

[5]  B. Klarner,et al.  Neuropsychological profile of adult patients with Niemann–Pick C1 (NPC1) mutations , 2007, Journal of Inherited Metabolic Disease.

[6]  M. Pineda,et al.  Niemann–Pick C disease in Spain: Clinical spectrum and development of a disability scale , 2006, Journal of the Neurological Sciences.

[7]  N. Baumann,et al.  The adult form of Niemann-Pick disease type C. , 2006, Brain : a journal of neurology.

[8]  D. Kipnis,et al.  Pregnane X receptor (PXR) activation: A mechanism for neuroprotection in a mouse model of Niemann–Pick C disease , 2006, Proceedings of the National Academy of Sciences.

[9]  M. Patterson,et al.  Therapy of Niemann-Pick disease, type C. , 2004, Biochimica et biophysica acta.

[10]  S. Mellon,et al.  Niemann–Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone , 2004, Nature Medicine.

[11]  D. Ory The niemann-pick disease genes; regulators of cellular cholesterol homeostasis. , 2004, Trends in cardiovascular medicine.

[12]  E. Nanba,et al.  Niemann–Pick type C disease: Accelerated neurofibrillary tangle formation and amyloid β deposition associated with apolipoprotein E ε4 homozygosity , 2002 .

[13]  R. Sokol,et al.  Niemann-Pick Disease Type C in Neonatal Cholestasis at a North American Center , 2002, Journal of pediatric gastroenterology and nutrition.

[14]  S. Walkley,et al.  Critical role for glycosphingolipids in Niemann-Pick disease type C , 2001, Current Biology.

[15]  H. Ninomiya,et al.  [Niemann-Pick disease type C]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.

[16]  S. Walkley,et al.  Neurons in Niemann‐Pick Disease Type C Accumulate Gangliosides as Well as Unesterified Cholesterol and Undergo Dendritic and Axonal Alterations , 2001, Journal of neuropathology and experimental neurology.

[17]  R. Wattiaux,et al.  Identification of HE1 as the second gene of Niemann-Pick C disease. , 2000, Science.

[18]  S. Sherlock,et al.  Niemann-Pick disease type C: diagnosis and outcome in children, with particular reference to liver disease. , 1993, The Journal of pediatrics.

[19]  R. Schiffmann,et al.  The effect of cholesterol‐lowering agents on hepatic and plasma cholesterol in Niemann‐Pick disease type C , 1993, Neurology.

[20]  S. Sato,et al.  A clinical staging classification for type C Niemann‐Pick disease , 1992, Neurology.

[21]  R. Brady,et al.  Group C Niemann‐Pick disease: faulty regulation of low‐density lipoprotein uptake and cholesterol storage in cultured fibroblasts , 1987, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  T. Starzl,et al.  Progression of neurovisceral storage disease with supranuclear ophthalmoplegia following orthotopic liver transplantation. , 1986, Pediatrics.

[23]  R. Brady,et al.  A defect in cholesterol esterification in Niemann-Pick disease (type C) patients. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Jacob Cohen A Coefficient of Agreement for Nominal Scales , 1960 .

[25]  E. Nanba,et al.  Niemann-Pick type C disease: accelerated neurofibrillary tangle formation and amyloid beta deposition associated with apolipoprotein E epsilon 4 homozygosity. , 2002, Annals of neurology.